Inflexion’s experience in our sector, steering acquisitions and the immense task of carve-outs made them incredibly well suited to our ambitions. They bring substantially more than pure capital to our plans.
Guy Clark, CEO, CNX Therapeutics
In 2021 Inflexion acquired CNX Therapeutics, a European pharmaceutical company dedicated to the supply of essential medicines. The business was formed when Inflexion acquired Sunovion Pharmaceuticals Europe Limited, the European operations of US-based Sunovion.
CNX Therapeutics is a European pharmaceutical company dedicated to the supply of essential medicines with a portfolio of speciality brands and hospital products.
The business was formed in August 2021 when Inflexion acquired Sunovion Pharmaceuticals Europe Limited, the European operations of US-based Sunovion. The carve out included the pan-European licensing rights to a patent-protected medicine used for the treatment of schizophrenia.
With substantial experience in successfully executing carve-outs, Inflexion is drawing on its healthcare expertise to establish CNX Therapeutics as a standalone business. We are supporting CNX Therapeutics to build its product portfolio to develop a scaled European platform. This will focus heavily on hospital and central nervous system therapies that stand to benefit from its existing infrastructure and capabilities.
Guy Clark, CEO, CNX Therapeutics